Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Nature Reviews. Cancer

• Publication date

  2019-03-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41568-019-0133-9PMID 30926931PMCID PMC6538259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

  2019cited by this paper
• Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition

  2019cited by this paper
• Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

  2018cited by this paper
• Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition.

  2018cited by this paper
• Abstract B08: Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition

  2018cited by this paper
• Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

  2018cited by this paper
• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

  2018cited by this paper
• Small Cell Lung Cancer subtypes identified by systems-level modeling of transcription factor networks

  2018cited by this paper
• Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

  2018cited by this paper
• First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

  2018cited by this paper
• POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

  2018cited by this paper
• Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin.

  2018cited by this paper
• Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

  2018cited by this paper
• Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.

  2018cited by this paper
• Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

  2018cited by this paper
• Faculty Opinions recommendation of The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.

  2018cited by this paper
• Correction: Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.

  2017cited by this paper
• Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

  2017cited by this paper
• LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.

  2017cited by this paper
• Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

  2017cited by this paper
• Unravelling the biology of SCLC: implications for therapy

  2017cited by this paper
• Small-cell lung cancer: what we know, what we need to know and the path forward

  2017cited by this paper
• Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.

  2017cited by this paper
• CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

  2017cited by this paper
• Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer

  2017cited by this paper
• Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

  2017cited by this paper
• SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer

  2017cited by this paper
• MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

  2017cited by this paper
• Skn-1a/Pou2f3 functions as a master regulator to generate Trpm5-expressing chemosensory cells in mice

  2017cited by this paper
• Abstract 1063: Benefit from combination cancer therapy arising from patient-to-patient variability rather than additive or synergistic drug action

  2017cited by this paper
• Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

  2017cited by this paper
• Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer

  2017cited by this paper
• Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

  2016cited by this paper
• Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive‐stage small cell lung cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E1508)

  2016cited by this paper
• Vasculogenic mimicry in small cell lung cancer

  2016cited by this paper
• Implications for Therapy

  2016cited by this paper
• ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.

  2016cited by this paper
• The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

  2015cited by this paper
• DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2

  2015cited by this paper
• Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.

  2015cited by this paper
• A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

  2015cited by this paper
• Comprehensive genomic profiles of small cell lung cancer

  2015cited by this paper
• Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis

  2015cited by this paper
• RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

  2015cited by this paper
• Comprehensive molecular profiling of lung adenocarcinoma

  2014cited by this paper
• Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

  2014cited by this paper
• Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

  2014cited by this paper
• Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.

  2013cited by this paper
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• Comprehensive genomic characterization of squamous cell lung cancers

  2012cited by this paper
• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

  2012cited by this paper
• Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

  2011cited by this paper
• A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.

  2011cited by this paper
• Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

  2010cited by this paper
• Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation

  2009cited by this paper
• Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympatho-adrenal lineage

  2008cited by this paper
• Targeted Disruption of NeuroD, a Proneural Basic Helix-Loop-Helix Factor, Impairs Distal Lung Formation and Neuroendocrine Morphology in the Neonatal Lung

  2008cited by this paper
• The zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells.

  2006cited by this paper
• Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification

  2006cited by this paper
• Hes6 Promotes Cortical Neurogenesis and Inhibits Hes1 Transcription Repression Activity by Multiple Mechanisms

  2003cited by this paper
• Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.

  2003cited by this paper
• Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium.

  2000cited by this paper
• Pathology of small-cell lung cancer

  2000cited by this paper
• Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

  1999cited by this paper
• An achaete-scute homologue essential for neuroendocrine differentiation in the lung

  1997cited by this paper
• The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies.

  1994cited by this paper
• Establishment and identification of small cell lung cancer cell lines having classic and variant features.

  1985cited by this paper
• Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

  1985cited by this paper
• Amplification and expression of the c-myc oncogene in human lung cancer cell lines

  1983cited by this paper
• Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties.

  1980cited by this paper

• SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.

  2026cites this paper
• Global advances and future directions in lung cancer care: expert consensus and strategic priorities

  2026cites this paper
• Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer.

  2026cites this paper
• Epigenetic remodeling and apoptotic activation by Chidamide suppress small cell lung cancer in molecularly distinct subtypes

  2026cites this paper
• Construction and immunotherapy application of lung cancer organoids.

  2026cites this paper
• 20 Years of Breakthroughs: Transforming the Fight Against Thoracic Malignancies.

  2026cites this paper
• EZH2 Inhibition Reshapes 3D Chromatin Architecture to Induce Immunogenic Phenotype in Small Cell Lung Cancer

  2026cites this paper
• Immunohistochemical profiling of small cell lung cancer reveals subtype heterogeneity and a tuft cell-like subtype characterized by LRMP and TRPM5.

  2026cites this paper
• Spatial transcriptomics reveals molecular heterogeneity and subtype-specific therapeutic targets in small cell lung cancer

  2026cites this paper
• Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumours.

  2026cites this paper
• Genomic alterations and their correlation with metabolic-related genes in lung cancer.

  2026cites this paper
• ScRNA-Seq: A way to reveal the potential mechanisms of metastasis in small cell lung cancer.

  2026cites this paper
• c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors

  2026cites this paper
• Tumor heterogeneity assessment using single-cell RNA sequencing (scRNA-seq): applications in lung cancer for diagnosis and treatment

  2026cites this paper
• Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugates.

  2026cites this paper
• Characterization of POU2F3-expressing large cell neuroendocrine carcinoma of the lung: A comprehensive analysis of morphology, immunohistochemistry, and genomic alterations.

  2026cites this paper
• Altered bacteriome and mycobiome in small cell lung cancer: insights from microbial profiling.

  2026cites this paper
• Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer.

  2026cites this paper
• RNA sequencing reveals differential expression of circular RNAs in human small cell lung cancer

  2026cites this paper
• Primary cutaneous non neuroendocrine small cell carcinoma POU2F3 subtype: morphologic, immunohistochemical, transcriptomic and methylation analysis of two cases.

  2026cites this paper
• Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC

  2026cites this paper
• Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping

  2026cites this paper
• EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy

  2026cites this paper
• Lineage plasticity: a new dilemma in lung cancer treatment

  2026cites this paper
• Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC.

  2026cites this paper
• Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.

  2026cites this paper
• A case of small cell lung cancer with multiple metastases and Y chromosome deletion

  2026cites this paper
• XPO1 as a key regulator in small cell lung cancer: mechanisms, biomarkers, and therapeutic implications

  2025cites this paper
• Modeling large cell neuroendocrine carcinoma of the lung for molecular, therapeutic and microenvironmental inferences: current knowledge and future perspectives

  2025influential citation
• Integrative epigenome and transcriptome analyses reveal transcriptional programs differentially regulated by ASCL1 and NEUROD1 in small cell lung cancer

  2025cites this paper
• Advancing therapeutics in small-cell lung cancer

  2025cites this paper
• ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer

  2025cites this paper
• Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

  2025cites this paper
• Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L).

  2025cites this paper
• Molecular basis and therapeutic implications of binary YAPOn/YAPOff cancer classes

  2025cites this paper
• Potential of C-X-C-Chemokine-Receptor-Type-4-Directed PET/CT Using [18F]AlF-NOTA-QHY-04 in Identifying Molecular Subtypes of Small Cell Lung Cancer

  2025cites this paper
• Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies.

  2025cites this paper
• Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC

  2025cites this paper
• Expression of insulinoma-associated protein 1 (INSM1) in gastric neuroendocrine and non-neuroendocrine neoplasms

  2025cites this paper
• Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study

  2025cites this paper
• Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center

  2025cites this paper
• What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer?

  2025cites this paper
• In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer

  2025cites this paper
• Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review

  2025cites this paper
• Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.

  2025cites this paper
• Proteogenomic Characterization of High-Grade Lung Neuroendocrine Carcinoma Deciphers Molecular Diversity and Potential Biomarkers of Different Histological Subtypes in Chinese Population

  2025cites this paper
• An organoid library unveils subtype-specific IGF-1 dependency via a YAP–AP1 axis in human small cell lung cancer

  2025cites this paper
• Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma

  2025cites this paper
• Metabolic reprogramming signature predicts prognosis and immune landscape in small cell lung cancer: MOCS2 validation and implications for personalized therapy

  2025cites this paper
• NeuroD1 is frequently expressed in Merkel cell polyomavirus-negative and keratin 20-negative Merkel cell carcinoma: A potential diagnostic pitfall.

  2025cites this paper
• Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer

  2025cites this paper
• FOXA2 promotes metastatic competence in small cell lung cancer

  2025cites this paper
• Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes

  2025cites this paper
• Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer

  2025cites this paper
• CoREST in pieces: Dismantling the CoREST complex for cancer therapy and beyond

  2025cites this paper
• The current and emerging immunotherapy paradigm in small-cell lung cancer

  2025cites this paper
• Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response.

  2025cites this paper
• AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study.

  2025cites this paper
• Prognostic Significance of Immunohistochemical Surrogate Molecular Sub‐Typing of Small Cell Lung Carcinoma

  2025cites this paper
• DeepTFtyper: an interpretable morphology-aware graph neural network for translating histopathology images into molecular subtypes in small cell lung cancer

  2025cites this paper
• Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes

  2025cites this paper
• Clinical needs and pathology’s answers in neuroendocrine neoplasms of the lung

  2025cites this paper
• Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation

  2025influential citation
• Challenges of small cell lung cancer heterogeneity and phenotypic plasticity

  2025cites this paper
• Roles of Annexin A1 Expression in Small Cell Lung Cancer

  2025cites this paper
• Current and future perspectives in extensive-stage small-cell lung cancer

  2025cites this paper
• Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer

  2025cites this paper
• Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer

  2025cites this paper
• Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer.

  2025cites this paper
• Brazilian real-world data of immunotherapy in extensive stage small cell lung cancer

  2025cites this paper
• Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response

  2025cites this paper
• Exploring resistance to initial chemotherapy in small cell lung cancer: The role of bone metastasis and other clinicopathologic characteristics

  2025cites this paper
• Extracellular Vesicular Delta‐Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer Diagnosis

  2025cites this paper
• Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapy

  2025cites this paper
• Significance of CD8+T cells related gene ITGB2 in prognosis and tumor microenvironment of small cell lung cancer

  2025cites this paper
• Differential expression of the MYC‐Notch axis drives divergent responses to the front‐line therapy in central and peripheral extensive‐stage small‐cell lung cancer

  2025influential citation
• Single-cell RNA sequencing reveals tumor heterogeneity in small cell neuroendocrine cervical carcinoma

  2025influential citation
• The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer

  2025cites this paper
• Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer.

  2025cites this paper
• A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors

  2025cites this paper
• Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor

  2025influential citation
• Whole-section digital analysis of immune profiles in surgically resected small cell lung carcinoma and their associations with molecular subtypes

  2025cites this paper
• PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer

  2025cites this paper
• Predictive Biomarker for SCLC Therapeutics: A Broken Promise or a Complex Disease With Missing Links.

  2025cites this paper
• Lethal co-expression intolerance underlies the mutually exclusive expression of ASCL1 and NEUROD1 in SCLC cells

  2025cites this paper
• KLF4 promotes a KRT13+ hillock-like state in squamous lung cancer

  2025cites this paper
• Advances in adoptive cell therapies in small cell lung cancer

  2025cites this paper
• [New perspectives in the management of small cell bronchial cancer].

  2025cites this paper
• Small Cell Lung Cancer: A Review.

  2025cites this paper
• Current and future therapies for small cell lung carcinoma

  2025influential citation
• Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives

  2025influential citation
• Immunohistochemical investigation of the transcription factor PROX1 emphasizing on neuroendocrine neoplasms.

  2025cites this paper
• The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity

  2025cites this paper
• Clinical Impact of POU2F3 Expression in Surgically Resected Pulmonary High-Grade Neuroendocrine Carcinoma

  2025cites this paper
• Current and future pharmacological therapies for extensive-stage small-cell lung cancer

  2025cites this paper
• Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer

  2025cites this paper
• CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer

  2025cites this paper
• Unlocking the Radiosensitizing Potential of MYC inhibition in Neuroendocrine Malignancies.

  2025cites this paper
• Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in small cell lung cancer

  2025cites this paper
• Intrinsic electrical activity drives small-cell lung cancer progression

  2025cites this paper